☰

Erik N. Rasmussen - Publications

Affiliations: 
National Severe Storms Laboratory National Oceanic and Atmospheric Administration, United States 
 Cooperative Institute for Mesoscale Meteorological Studies University of Oklahoma, Norman, OK, United States 
Tree Info Similar researchers PubMed Report error

0/41 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
Low-probability matches (unlikely to be authored by this person)
2025 Katlinskaya Y, Panwar B, Zeng Y, Gordon P, Rasmussen E, Naegele V, Klinger M, Zugmaier G. Pooled biomarker analysis of the association of baseline T regulatory cells with response and T-cell recovery profiles with blinatumomab treatment. The Oncologist. 30. PMID 40515477 DOI: 10.1093/oncolo/oyaf137  0.01
2023 Post AR, Ho N, Rasmussen E, Post I, Cho A, Hofer J, Maness AT, Parnell T, Nix DA. Hypermedia-based software architecture enables Test-Driven Development. Jamia Open. 6: ooad089. PMID 37860604 DOI: 10.1093/jamiaopen/ooad089  0.01
2022 Krogh SB, Jensen TS, Rolving N, Thomsen JNL, Hansen CB, Werenberg CH, Rasmussen E, Carlson R, Jensen RK. Appropriateness of referrals from primary care for lumbar MRI. Chiropractic & Manual Therapies. 30: 9. PMID 35193634 DOI: 10.1186/s12998-022-00418-4  0.01
2021 Cuyun Carter G, Sheffield KM, Gossai A, Huang YJ, Zhu YE, Bowman L, Nash Smyth E, Mathur R, Cohen AB, Rasmussen E, Balakrishna S, Morato Guimaraes C, Rybowski S, Seidman AD. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer. Current Medical Research and Opinion. 1. PMID 33970738 DOI: 10.1080/03007995.2021.1923468  0.01
2021 Krogh SB, Jensen TS, Rolving N, Laursen M, Thomsen JNL, Hansen CB, Werenberg CH, Rasmussen E, Carlson R, Jensen RK. Categorisation of lumbar spine MRI referrals in Denmark as compliant or non-compliant to international imaging guidelines: an inter-rater reliability study. Chiropractic & Manual Therapies. 29: 12. PMID 33761956 DOI: 10.1186/s12998-021-00370-9  0.01
2020 Herbst RS, Arkenau HT, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, Mi G, Wang H, Rasmussen E, Ferry D, Chao BH, et al. Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33068794 DOI: 10.1016/j.jtho.2020.10.004  0.01
2020 Razak AR, Cleary JM, Moreno V, Boyer M, Calvo Aller E, Edenfield W, Tie J, Harvey RD, Rutten A, Shah MA, Olszanski AJ, Jäger D, Lakhani N, Ryan DP, Rasmussen E, et al. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. Journal For Immunotherapy of Cancer. 8. PMID 33046621 DOI: 10.1136/jitc-2020-001006  0.01
2020 Lee HC, Raje NS, Landgren O, Upreti VV, Wang J, Avilion AA, Hu X, Rasmussen E, Ngarmchamnanrith G, Fujii H, Spencer A. Letter phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia. PMID 32317775 DOI: 10.1038/s41375-020-0834-9  0.01
2020 Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, Krönke J, Facon T, Salnikov AV, Lesley R, Beutner K, Kalabus J, Rasmussen E, Riemann K, Minella AC, et al. Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 38: 775-783. PMID 31895611 DOI: 10.1200/JCO.19.02657  0.01
2019 Gluck WL, Gounder MM, Frank R, Eskens F, Blay JY, Cassier PA, Soria JC, Chawla S, de Weger V, Wagner AJ, Siegel D, De Vos F, Rasmussen E, Henary HA. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Investigational New Drugs. PMID 31359240 DOI: 10.1007/s10637-019-00840-1  0.01
2019 Erba HP, Becker PS, Shami PJ, Grunwald MR, Flesher DL, Zhu M, Rasmussen E, Henary HA, Anderson AA, Wang ES. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. Blood Advances. 3: 1939-1949. PMID 31253596 DOI: 10.1182/bloodadvances.2019030916  0.01
2019 Rosenthal M, Curry R, Reardon DA, Rasmussen E, Upreti VV, Damore MA, Henary HA, Hill JS, Cloughesy T. Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer Chemotherapy and Pharmacology. PMID 31154523 DOI: 10.1007/s00280-019-03879-2  0.01
2019 Massard C, Soria JC, Krauss J, Gordon M, Lockhart AC, Rasmussen E, Upreti VV, Patel S, Ngarmchamnanrith G, Henary H. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma. Cancer Chemotherapy and Pharmacology. PMID 30915497 DOI: 10.1007/s00280-019-03796-4  0.01
2018 Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso PM, Rasmussen E, Juan G, Upreti VV, Beers C, Ngarmchamnanrith G, Schöffski P. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. Journal For Immunotherapy of Cancer. 6: 93. PMID 30253804 DOI: 10.1186/s40425-018-0407-x  0.01
2018 Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, Goodman OB, Rasmussen E, Chow V, Juan G, Friberg GR, Gamelin E, Vogl FD, Desai J. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Investigational New Drugs. PMID 29980894 DOI: 10.1007/s10637-018-0625-6  0.01
2018 Quina MJ, Bontempi E, Bogush A, Schlumberger S, Weibel G, Braga R, Funari V, Hyks J, Rasmussen E, Lederer J. Technologies for the management of MSW incineration ashes from gas cleaning: New perspectives on recovery of secondary raw materials and circular economy. The Science of the Total Environment. 635: 526-542. PMID 29679825 DOI: 10.1016/j.scitotenv.2018.04.150  0.01
2017 Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, Rasmussen E, Amore B, Nagorsen D, Hill JS, Stephenson J. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients With Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28655795 DOI: 10.1158/1078-0432.CCR-16-3261  0.01
2017 Kantarjian HM, Schuster MW, Jain N, Advani A, Jabbour E, Gamelin E, Rasmussen E, Juan G, Anderson A, Chow VF, Friberg G, Vogl FD, Sekeres MA. A Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients With Acute Myeloid Leukemia. American Journal of Hematology. PMID 28370201 DOI: 10.1002/ajh.24736  0.01
2016 Dowlati A, Vlahovic G, Natale R, Rasmussen E, Singh I, Hwang YC, Rossi J, Bass MB, Friberg G, Pickett CA. A Phase 1, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients With Advanced Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27076631 DOI: 10.1158/1078-0432.Ccr-15-2145  0.01
2016 Fletcher SP, Chin DJ, Gruenbaum L, Bitter H, Rasmussen E, Ravindran P, Swinney DC, Birzele F, Schmucki R, Lorenz SH, Kopetzki E, Carter J, Triyatni M, Thampi LM, Yang J, et al. Correction: Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B. Plos Pathogens. 12: e1005541. PMID 27022978 DOI: 10.1371/journal.ppat.1005541  0.01
2015 Fletcher SP, Chin DJ, Gruenbaum L, Bitter H, Rasmussen E, Ravindran P, Swinney DC, Birzele F, Schmucki R, Lorenz SH, Kopetzki E, Carter J, Triyatni M, Thampi LM, Yang J, et al. Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B. Plos Pathogens. 11: e1005103. PMID 26352406 DOI: 10.1371/Journal.Ppat.1005103  0.01
2015 Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman MH, Ginzler EM, Cooke B, Holloway D, Kaliyaperumal A, Kuchimanchi KR, Cheah TC, Rasmussen E, Ferbas J, Belouski SS, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Research & Therapy. 17: 215. PMID 26290435 DOI: 10.1186/s13075-015-0741-z  0.01
2015 Wu B, Melara R, Rasmussen E, Zhou L, Wong T, Kitahara C, Ma M, Lu J, Gamelin E, Pickett CA, Sun YN. Pharmacokinetic drug-drug interaction assessment of peptibody trebananib in combination with chemotherapies. Cancer Chemotherapy and Pharmacology. 76: 243-50. PMID 26032239 DOI: 10.1007/s00280-015-2748-1  0.01
2015 Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Investigational New Drugs. 33: 691-9. PMID 25895965 DOI: 10.1007/s10637-015-0236-4  0.01
2014 Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget. 5: 11154-67. PMID 25525888 DOI: 10.18632/Oncotarget.2568  0.01
2014 Padhi D, Higano CS, Shore ND, Sieber P, Rasmussen E, Smith MR. Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. The Journal of Clinical Endocrinology and Metabolism. 99: E1967-75. PMID 24971661 DOI: 10.1210/jc.2014-1271  0.01
2014 Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clinical Genitourinary Cancer. 12: 167-177.e2. PMID 24365125 DOI: 10.1016/J.Clgc.2013.11.007  0.01
2014 Tan AT, Hoang LT, Chin D, Rasmussen E, Lopatin U, Hart S, Bitter H, Chu T, Gruenbaum L, Ravindran P, Zhong H, Gane E, Lim SG, Chow WC, Chen PJ, et al. Reduction of HBV replication prolongs the early immunological response to IFNα therapy Journal of Hepatology. 60: 54-61. PMID 23994382 DOI: 10.1016/j.jhep.2013.08.020  0.01
2012 Chariker M, Ford R, Rasmussen E, Schotter E. CASE REPORT Management of Periauricular and Auricular Necrotizing Wound From Brown Recluse Spider Bite Using Negative Pressure Wound Therapy and Wound Interface Modulation. Eplasty. 12: e26. PMID 22720113  0.01
2012 Lu JF, Rasmussen E, Karlan BY, Vergote IB, Navale L, Kuchimanchi M, Melara R, Stepan DE, Weinreich DM, Sun YN. Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemotherapy and Pharmacology. 69: 1135-44. PMID 22210018 DOI: 10.1007/s00280-011-1787-5  0.01
2010 Mikaelian I, Buness A, de Vera-Mudry MC, Kanwal C, Coluccio D, Rasmussen E, Char HW, Carvajal V, Hilton H, Funk J, Hoflack JC, Fielden M, Herting F, Dunn M, Suter-Dick L. Primary endothelial damage is the mechanism of cardiotoxicity of tubulin-binding drugs. Toxicological Sciences : An Official Journal of the Society of Toxicology. 117: 144-51. PMID 20624997 DOI: 10.1093/Toxsci/Kfq189  0.01
2010 Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, Le N, LoRusso P. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors Clinical Cancer Research. 16: 3044-3056. PMID 20501621 DOI: 10.1158/1078-0432.CCR-09-3368  0.01
2010 Belouski SS, Wallace D, Weisman M, Ishimori M, Hendricks L, Zack D, Vincent M, Rasmussen E, Ferbas J, Chung J. Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus. Cytometry. Part B, Clinical Cytometry. 78: 49-58. PMID 19670351 DOI: 10.1002/cyto.b.20482  0.01
2009 Mikaelian I, Coluccio D, Hirkaler GM, Downing JC, Rasmussen E, Todd J, Estis J, Lu QA, Nicklaus R. Assessment of the toxicity of hydralazine in the rat using an ultrasensitive flow-based cardiac troponin I immunoassay. Toxicologic Pathology. 37: 878-81. PMID 19854888 DOI: 10.1177/0192623309351894  0.01
2009 Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3557-65. PMID 19546406 DOI: 10.1200/Jco.2008.19.6683  0.01
2008 Mikaelian I, Coluccio D, Morgan KT, Johnson T, Ryan AL, Rasmussen E, Nicklaus R, Kanwal C, Hilton H, Frank K, Fritzky L, Wheeldon EB. Temporal gene expression profiling indicates early up-regulation of interleukin-6 in isoproterenol-induced myocardial necrosis in rat. Toxicologic Pathology. 36: 256-64. PMID 18413786 DOI: 10.1177/0192623307312696  0.01
2006 Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. The New England Journal of Medicine. 354: 1021-30. PMID 16525139 DOI: 10.1056/NEJMoa053583  0.01
2006 Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 107: 2633-8. PMID 16322468 DOI: 10.1182/blood-2005-10-4084  0.01
2004 Dhodapkar MV, Hussein MA, Rasmussen E, Solomon A, Larson RA, Crowley JJ, Barlogie B. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood. 104: 3520-6. PMID 15308571 DOI: 10.1182/blood-2004-05-1924  0.01
2004 Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, Strachan E, Crainie M, Walker R, Belch AR, Pilarski LM, Barlogie B, Shaughnessy J, Reiman T. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood. 104: 1151-8. PMID 15105292 DOI: 10.1182/blood-2003-11-4079  0.01
2004 Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. The New England Journal of Medicine. 349: 2483-94. PMID 14695408 DOI: 10.1056/NEJMoa030847  0.01
Hide low-probability matches.